



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Aladar Szalay et al. Art Unit : 1632
Serial No. : 10/849,664 Examiner : Not yet Assigned
Filed : May 19, 2004 Conf. No. : 7765 Cust. No. 20985
Title : LIGHT EMITTING MICROORGANISMS AND CELLS FOR DIAGNOSIS
AND THERAPY OF DISEASES ASSOCIATED WITH WOUNDED OR
INFLAMED TISSUE

Mail Stop: Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (9 pages) and cited references for filing in connection with the above-captioned application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first Office Action on the merits for the above-captioned application, a fee for filing this statement should not be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:



The Commissioner is hereby authorized to charge the fee for the extension of time and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie L. Seidman
Reg. No. 33,779

Dated: February 16, 2005

Attorney Docket No. 17248-004002 / 4804B

Address all correspondence to:

Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com
10485001.doc

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Aladar Szalay et al. Art Unit : 1632
Serial No. : 10/849,664 Examiner : Unknown
Filed : May 19, 2004 Conf. No. : 7765 Cust. No. 20985
Title : LIGHT EMITTING MICROORGANISMS AND CELLS FOR DIAGNOSIS
AND THERAPY OF DISEASES ASSOCIATED WITH WOUNDED OR
INFLAMED TISSUE

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN
ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

Because this Supplemental Information Disclosure Statement is filed before the receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (9 pages) and copies of the cited non U.S. Patent documents are provided herewith.

The documents cited on the Forms PTO-1449 are in the English language, with the exception of items noted below. Items DQ (Mayr et al.) is in the German language and includes an English language abstract on the first page of the article. Items FT (Timiriasova et al.) is in the Russian language includes an English language abstract on the last page of the article. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant : Aladar Szalay et al.
Serial No. : 10/849,664
Filed : May 19, 2004
Supplemental IDS
Page : 2 of 2

Attorney's Docket No.: 17248-004002 / 4804B

Applicant also makes known to the Examiner the following pending U.S applications that have one or more common inventors and/or are commonly owned:

Application No.	Filing Date	Matter No.
US 10/485,179	01/28/04	003US1 (4803US)

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Respectfully submitted,


Stephanie Seidman
Reg. No. 33,779

Dated: February 16, 2005

Attorney Docket No. 17248-004002 / 4804B

Address all correspondence to:

Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-5070
Facsimile: (202) 626-7796
email: seidman@fr.com



Sheet 1 of 9

Substitute Form PTO-1449 (Modified)				U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004002/ 4804B		Application No. 10/849,664	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Aladar Szalay et al.					
				Filing Date May 19, 2004			Group Art Unit 1632		
U.S. Patent Documents									
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate		
	AA	2003/0009015	01/09/03	Ulrich et al.	536	23.1	06/25/97		
	AB	2003/0031681	02/13/03	Mc Cart et al.	424	186.1	11/13/01		
	AC	2003/0086906	05/08/03	Mastrangelo et al.	424	93.2	11/04/02		
	AD	2003/0165465	09/04/03	Roberts et al.	424	93.2	06/13/02		
	AE	2003/0198627	10/23/03	Arts et al.	424	93.21	08/23/02		
	AF	2003/0228330	12/11/03	Falkner et al.	424	232.1	03/14/03		
	AG	4,722,848	02/02/88	Paoletti et al.	424	199.1	06/19/84		
	AH	5,693,533	12/02/97	Raney et al.	435	366	12/07/94		
	AI	5,718,902	02/17/98	Yilma et al.	424	211.1	06/17/91		
	AJ	5,830,702	11/03/98	Portnoy et al.	435	69.3	12/30/94		
	AK	6,093,700	07/25/00	Mastrangelo et al.	514	44	02/20/97		
	AL	6,190,657	02/20/01	Pawelek et al.	424	93.1	06/04/96		
	AM	6,428,968	08/06/02	Molnar-Kimber et al.	435	7.23	11/08/99		
	AN	6,455,673	09/24/02	Collier	530	350	02/16/99		
	AO	6,548,068	04/15/03	Schlom et al.	424	199.1	01/07/00		
	AP	6,596,279	07/22/03	Paoletti et al.	424	199.1	08/14/98		
	AQ	6,627,160	09/03/03	Wold et al.	424	93.2	09/19/01		
	AR	6,685,935	02/03/04	Pawelek et al.	424	93.2	07/21/99		

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
	AS	0 037 441	10/14/81	EP, A1			Yes
	AT	0 037 441	05/09/84	EP, B1			No
	AU	03/045153	06/05/03	PCT A1			
	AV	03/102168	12/11/03	PCT A1			
	AW	1 281 777	02/05/03	EP A1			
	AX	99/32646	07/01/99	PCT			

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.			
		Filing Date May 19, 2004	Group Art Unit 1632		

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
	AY	"Generation of Recombinant Vaccinia Viruses," Unit 16.17 in <i>Short Protocols in Molecular Biology 2nd edition: a compendium of Methods from Current Protocols in Molecular Biology</i> , Green Publishing and Wiley-Interscience Supplement 15:16.71-16.82 (1992)	
	AZ	Adonai <i>et al.</i> , "Ex vivo cell labeling with ⁶⁴ Cu-pyruvaldehyde-bis(N ⁴ -methylthiocarbonylazone) for imaging cell trafficking in mice with positron-emission tomography," Proc. Natl. Acad. Sci. USA 99: 3030-3035 (2002)	
	BA	Altschul <i>et al.</i> , "Basic local alignment search tool," J Molec Biol 215:403-410 (1990)	
	BB	Ando, N. and M. Matumoto, "Unmasking of growth of dermovaccinia strain dairen I in L cells by acid treatment of cells after virus adsorption," Japan. J. Microbiol. 14(3): 181-186 (1979)	
	BC	Antoine <i>et al.</i> , "The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses," Virology 244: 365-396 (1998)	
	BD	ATCC Accession No. 59324	
	BE	ATCC Accession No. 59325	
	BF	ATCC Accession Nos. CCL-121	
	BG	ATCC Accession Nos. CRL-12011	
	BH	ATCC Accession Nos. CRL-12012	
	BI	ATCC catalog no. 700294	
	BJ	ATCC No. CCL-107	
	BK	ATCC No. CRL-6475	
	BL	ATCC under Accession number: VR-1549	
	BM	Barrett <i>et al.</i> , "Yellow Fever Vaccines," Biologicals 25:17-25 (1997)	
	BN	Bauerschnitz <i>et al.</i> , "Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus," Cancer Research 62: 1266-1270 (2002)	
	BO	Benes <i>et al.</i> , "M13 and pUC vectors with new unique restriction sites for cloning," Gene 130: 151-152 (1993)	
	BP	Bernards <i>et al.</i> , "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector," Proc. Natl. Acad. Sci. USA 84: 6854-6858 (1987)	
	BQ	Beshara <i>et al.</i> , "Kinetic analysis of ⁵² Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography," Br. J. Haematol. 104: 288-295 (1999)	
	BR	Beshara <i>et al.</i> , "Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography," Br. J. Haematol. 104: 296-302 (1999)	
	BS	Bisno <i>et al.</i> , "Streptococcal infections of skin and soft tissues," N. Engl. J. Med. 334(4): 240-245 (1996)	
	BT	Blakemore, "Magnetotactic Bacteria," Annu. Rev. Microbiol. 36: 217-238 (1982)	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.		
		Filing Date May 19, 2004	Group Art Unit 1632	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	BU	Broder, C.C. and P.L. Earl, "Recombinant Vaccinia Viruses," <i>Mol. Biotechnol.</i> 13: 223-245 (1999)
	BV	Brouqui, P. and D. Raoult, "Endocarditis due to rare and fastidious bacteria," <i>Clinical Microbiology Reviews</i> 14(1): 177-207 (2001)
	BW	Calonder <i>et al.</i> , "Kinetic modeling of ⁵² Fe/ ^{52m} Mn-Citrate at the Blood-Brain Barrier by Positron Emission Tomography," <i>J. Neurochem.</i> 73: 2047-2055 (1999)
	BX	Carrillo and Lipman <i>et al.</i> , "The Multiple Sequence Alignment Problem in Biology," <i>SIAM J Applied Math</i> 48:1073-1082 (1988)
	BY	Chakrabarti <i>et al.</i> , "Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques," <i>Mol. Cell Biol.</i> 5:3403-3409 (1985)
	BZ	Chakrabarti <i>et al.</i> , "Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression," <i>BioTechniques</i> 23(6): 1094-1097 (1997)
	CA	Chamberlain <i>et al.</i> , "Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines," <i>Cancer Res.</i> 56: 2832-2836 (1996)
	CB	Child <i>et al.</i> , "Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence <i>in vivo</i> ," <i>Virology</i> 174:625-629 (1990)
	CC	Colinas <i>et al.</i> , "A DNA ligase gene in the copenhagen strain of vaccinia virus is nonessential for viral replication and recombination," <i>Virology</i> 179: 267-275 (1990)
	CD	Cusumano <i>et al.</i> , "Synergic activities of streptococcal pyrogenic exotoxin A and lipoteichoic acid in cytokine induction," <i>Microbiologica</i> 23(1): 37-45 (2000)
	CE	Davison, A. J. and B. Moss, "Structure of Vaccinia Virus Early Promoters," <i>J. Mol. Biol.</i> 210: 749-769 (1989)
	CF	Davison <i>et al.</i> , "New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins," <i>Nucleic Acids Research</i> 18: 4285-4286 (1990)
	CG	Devereux, J., <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX," <i>Nucleic Acids Research</i> 12(1): 387-95 (1984)
	CH	Earl <i>et al.</i> , "T-Lymphocyte Priming and Protection Against Friend Leukemia by Vaccinia-Retrovirus env Gene Recombinant," <i>Science</i> 234: 728-731 (1986)
	CI	Ebert <i>et al.</i> , "Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats," <i>Cancer Research</i> 63: 3605-3611 (2003)
	CJ	Ebert <i>et al.</i> , "Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer," <i>Cancer Research</i> 64: 3265-3270 (2004)
	CK	Estin <i>et al.</i> , "Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy," <i>Proc. Natl. Acad. Sci. USA</i> 85: 1052-1056 (1988)
	CL	Ferretti <i>et al.</i> , "Complete genome sequence of an M1 strain of <i>Streptococcus pyogenes</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 98(8): 4658-4663 (2001)
	CM	Flexner <i>et al.</i> , "Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen," <i>Nature</i> 355:259-262 (1988)
	CN	Flexner <i>et al.</i> , "Characterization of Human Immunodeficiency Virus gag/pol Gene Products Expressed by Recombinant Vaccinia Viruses," <i>Virology</i> 166: 339-349 (1988)
	CO	Giedlin <i>et al.</i> , "Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from <i>Field's Virology</i> ?" <i>Cancer Cell</i> 4: 241-243 (2003)
	CP	Goebel <i>et al.</i> , "The complete DNA sequence of vaccinia virus," <i>Virology</i> 179:247-266 (1990)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Aladar Szalay et al.	
(37 CFR §1.98(b))		Filing Date May 19, 2004	Group Art Unit 1632

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	CQ	Goebel et al., "Appendix to 'The complete DNA Sequence of Vaccinia Virus,'" <i>Virology</i> 179: 517-563 (1990)
	CR	Green et al., "Necrotizing Fasciitis," <i>Chest</i> 110(1):219-229 (1996)
	CS	Greinwald et al., "Treatment of lymphangiomas in children: an update of Picibanil (Ok-432) sclerotherapy," <i>Otolaryngol Head Neck Surg</i> 121(4): 381-387 (1999)
	CT	Gribskov et al., "Sigma factors from <i>E. coli</i> , <i>B. subtilis</i> , phage SP01, and phage T4 are homologous proteins," <i>Nucl. Acids Res.</i> 14:6745-6763 (1986)
	CU	Huang et al., "Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice," <i>Mol. Ther.</i> 8(3): 434-440 (2003)
	CV	Hurst et al., "A novel model of a metastatic human breast tumour xenograft line," <i>Br. J. Cancer</i> 68: 274-276 (1993)
	CW	Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence," <i>Proc Natl Acad Sci U S A.</i> 89:628-632 (1992)
	CX	Johnson et al., "An update on the vaccinia virus genome," <i>Virology</i> 196: 381-401 (1993)
	CY	Kantor et al., "Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine," <i>J. Natl. Cancer Inst.</i> 84: 1084-1091 (1992)
	CZ	Katz et al., "Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein," <i>J. Virology</i> 77:12266-12275 (2003)
	DA	Kotwal et al., "Mapping and Insertional Mutagenesis of a Vaccinia Virus Gene Encoding a 13, 800-Da Secreted Protein," <i>Virology</i> 171:579-587 (1989)
	DB	Kozak, M., "Structural features in Eukaryotic mRNAs that modulate the Initiation of Translation," <i>J. Biol. Chem.</i> 266:19867-19870 (1991)
	DC	Lamberton et al., "Construction and characterization of a bioluminescent <i>Streptococcus pyogene</i> ," <i>Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence</i> "Progress & Current Applications, Stanley, P.E. and L.J. Kricka et al.(Eds). World Scientific Publishing Co. Pte. Ltd., pp 85-88 (2002)
	DD	Lamberton et al., "Generation and characterization of a bioluminescent <i>Streptococcus pyogenes</i> ," <i>Proceedings of the 12th International Symposium on Bioluminescence & Chemiluminescence: 5-9 April 2002, Robinson College, University of Cambridge, UK</i> , p 3.22 (2002)
	DE	Lathe et al., "Tumour prevention and rejection with recombinant vaccinia," <i>Nature (London)</i> 326: 878-880 (1987)
	DF	Lee et al. "Prodrug and antedrug: two diametrical approaches in designing safer drugs," <i>Arch. Pharm. Res.</i> 25(2): 111-136 (2002)
	DG	Lee et al., "Molecular attenuation of vaccinia virus: mutant generation and animal characterization," <i>Journal of Virology</i> 66:2617-2630 (1992)
	DH	Leenders et al., "Blood to brain iron uptake in one Rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol," <i>J. Neural Transm. Suppl.</i> 43: 123-132 (1994)
	DI	Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment," <i>Gene Therapy</i> 4: 791-796 (1997)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.		
		Filing Date May 19, 2004	Group Art Unit 1632	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	DJ	Lemmon et al., "Anaerobic bacteria as a gene delivery system to tumors," Proceedings of the 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA April 10-13, 1994, published in: Proc. Am. Cancer Research Assn 35: 374 (1994)
	DK	Lewis et al., "Comparison of Four ⁶⁴ Cu-Labeled Somatostatin Analogs in Vitro and in a Tumor-Bearing Rat Model: Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy," J. Med. Chem. 42: 1341-1347 (1999)
	DL	Li et al., "Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective Inhibitor of angiogenesis and hypoxic tumor growth," Cancer Gene Therapy 10: 105-111 (2003)
	DM	Liau et al., "Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens," J. Neurosurg. 90(6): 1115-1124 (1999)
	DN	Liu et al., "An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency," Molecular Therapy 9(6): 786-803 (2004)
	DO	Lopez et al., "Infections in children with malignant disease in Argentina," Cancer 47(5): 1023-1030 (1981)
	DP	Mayford et al., "CaMKII Regulates the Frequency-Response Function of Hippocampal Synapses for the Production of Both LTD and LTP," Cell 81: 891-904 (1995)
	DQ	Mayr et al., "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defense Mechanism," Zentbl. Bakteriol. Hyg. Abt 1 Orig. B 167: 375-390 (1978) [In German, English abstract on first page of article]
	DR	McAllister et al., "Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases," J. Virol. 74:9197-9205 (2000).
	DS	McAneny et al., "Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer," Ann. Surg. Oncol. 3(5): 495-500 (1996)
	DT	Mikryukov et al., "Structural-functional organization of segment of vaccinia virus genome," Soviet Biotechnology (Biotehnologiya) 4: 19-25 (1988) [corresponds to pages 442-449 in the Russian language edition]
	DU	Moore et al., "Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor," EMBO J. 1992 11:1973-1980, corrigendum in The EMBO Journal 11(9): 3490 (1992)
	DV	Moss, B., "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," Proc. Natl. Acad. Sci. USA 93: 11341-11348 (1996)
	DW	Moss, B., "Poxvirus vectors: cytoplasmic expression of transferred genes," Curr. Opin. Genet. Dev. 3: 86-90 (1993)
	DX	Mullen et al., "Viral Oncolysis," The Oncologist 7: 106-119 (2002)
	DY	Mulryan et al., "Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors," Mol Cancer Ther 1(12): 1129-1137 (2002)
	DZ	Munagala et al., "The purine nucleoside phosphorylase from <i>Trichomonas vaginalis</i> is a homologue of the bacterial enzyme," Biochemistry 41(33): 10382-10389 (2002)

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.		
		Filing Date May 19, 2004	Group Art Unit 1632	
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	EA	NCBI Protein AAA48282		
	EB	NCBI Nucleotide AF012825		
	EC	NCBI Nucleotide. AF095689		
	ED	NCBI Nucleotide AF380138		
	EE	NCBI Nucleotide AX003206		
	EF	NCBI Nucleotide. AY009089		
	EG	NCBI Nucleotide AY243312		
	EH	NCBI Nucleotide AY484669		
	EI	NCBI Nucleotide AY603355		
	EJ	NCBI Nucleotide M35027		
	EK	NCBI Nucleotide M57977		
	EL	NCBI Nucleotide U94848		
	EM	NCBI Nucleotide X69198		
	EN	NCBI Nucleotide X94355		
	EO	Needleman <i>et al.</i> , "A general method applicable to the search for similarities in the amino acid sequences of two proteins," <i>J. Mol. Biol.</i> 48:443-453 (1970)		
	EP	Nograday, T., <i>Medicinal Chemistry A Biochemical Approach</i> , New York: Oxford University Press, pages 388-392 (1985)		
	EQ	Oerthli <i>et al.</i> , "Non-replicating recombinant vaccinia virus encoding murine B-7 molecules effective costimulation of naive CD4 ⁺ splenocytes <i>in vitro</i> ," <i>J. Gen. Virol.</i> 77: 3121-3125 (1996)		
	ER	Okamoto <i>et al.</i> , "Severe impairment of anti-cancer effect of lipoteichoic acid-relatedmolecule isolated from a penicillin-killed <i>Streptococcus pyogenes</i> in toll-like receptor 4-deficient mice," <i>International Immunopharmacology</i> 1(9-10): 1789-1795 (2001)		
	ES	Patel <i>et al.</i> , "A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells," <i>Proc. Natl. Acad. Sci. USA</i> 85: 9431-9435 (1988)		
	ET	Pawelek <i>et al.</i> , "Tumor-targeted <i>Salmonella</i> as a Novel Anticancer Vector," <i>Cancer Therapy</i> 57: 4537-4544 (1997)		
	EU	Pearson <i>et al.</i> , "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. USA</i> 85:2444-2448 (1988)		
	EV	Pilcher, H., "GM Bug activates cancer drug: Bacteria targets medicine to shrivel mouse tumours," news @ nature.com, Published online: 22 April 2004; http://www.nature.com/news/2004/040419/full/040419-9.html , (accessed on November 18, 2004)		
	EW	Pinkert <i>et al.</i> , "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," <i>Genes & Dev.</i> 1: 268-76 (1987)		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.		
		Filing Date May 19, 2004	Group Art Unit 1632	
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	EX	Plucienniczak et al., "Nucleotide sequence of a cluster and late genes in a conserved segment of the vaccinia virus genome," <i>Nucleic Acids Research</i> 13(3): 993-998 (1985)		
	EY	Puhlmann et al., "Vaccinia virus as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant," <i>Cancer Gene Therapy</i> 7(1): 66-73 (2000)		
	EZ	Qin, H. and S.K. Chatterjee, "Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF," <i>Human Gene Ther.</i> 7: 1853-1860 (1996)		
	FA	Rao et al., "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines," <i>J. Immunol.</i> 156: 3357-3365 (1996)		
	FB	Rodriguez et al., "Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses," <i>Proc. Natl. Acad. Sci. USA</i> 86: 1287-1291 (1989)		
	FC	Rolston et al., "In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients in cancer," <i>Antimicrob. Agents Chemother.</i> 34(11):2137-2141 (1990)		
	FD	Roseman et al., "The vaccinia virus HindIII fragment: nucleotide sequence of the left 6.2kb," <i>Virology</i> 178: 410-418 (1990)		
	FE	Roth et al., "p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge," <i>Proc. Natl. Acad. Sci. USA</i> 93: 4781-4786 (1996)		
	FF	Schwartz and Dayhoff, eds., <i>ATLAS OF PROTEIN SEQUENCE AND STRUCTURE</i> , National Biomedical Research Foundation, pp. 353-358 (1979)		
	FG	Shilo, B. and R.A. Weinberg, "DNA sequences homologous to vertebrate oncogenes are conserved in <i>Drosophila melanogaster</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 78:6789-6792 (1981)		
	FH	Shinozaki et al., "Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus," <i>Mol. Ther.</i> 9(3): 368-376 (2004)		
	FI	Silva et al., "Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase," <i>Protein Expr. Purif.</i> 27(1): 158-164 (2003)		
	FJ	Smith, T.F. and M.S. Waterman, "Comparison of biosequences," <i>Adv. Appl. Math.</i> 2:482-489 (1981)		
	FK	Sorscher et al., "Tumor cell bystander killing in colonic carcinoma utilizing the <i>Escherichia coli</i> <i>DeoD</i> gene to generate toxic purines," <i>Gene Therapy</i> 1(4): 233-238 (1994)		
	FL	Stevens, D.L., "Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment," <i>Emerg. Infect. Dis.</i> 1(3): 69-78 (1995)		
	FM	Sugimoto, M. and K. Yamanouchi, "Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines," <i>Vaccine</i> 12(8): 675-681 (1994)		
	FN	Sugimoto et al., "Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister Original (LO) strains," <i>Microbial. Immunol.</i> 29: 421-428 (1985)		
	FO	Suvorov et al., "Physical and genetic chromosomal map of an M type 1 strain of <i>Streptococcus pyogenes</i> ," <i>J. Bacteriol.</i> 178(18): 5546-5549 (1996)		
	FP	Suzuki et al., "Management of orbital lymphangioma using intralesional injection of OK-432," <i>Br. J. Ophthalmol.</i> 84(6): 614-617 (2000)		
	FQ	Sze et al., "Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival," <i>J. Vasc. Interv. Radiol.</i> 14(3): 279-290 (2003)		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.		
		Filing Date May 19, 2004	Group Art Unit 1632	
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	FR	Takahashi-Nishimaki <i>et al.</i> , "Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination," <i>J. Gen. Virol.</i> 68: 2705-2710 (1987)		
	FS	Theys <i>et al.</i> , "Tumor-specific gene delivery using genetically engineered bacteria," <i>Curr Gene Ther</i> 3(3): 207-221 (2003)		
	FT	Timiriasova <i>et al.</i> , "[Analysis of reporter gene expression at different segments of the vaccinia virus genome]," <i>Mol. Biol. (Mosk.)</i> 27(2): 392-401 (1993) [article in Russian, English abstract on last page of article]		
	FU	Timiryasova <i>et al.</i> , "Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper," <i>BioTechniques</i> 31: 534-540 (2001)		
	FV	Toth <i>et al.</i> , "An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated <i>Wnt</i> signaling," <i>Cancer Research</i> 64: 3638-3644 (2004)		
	FW	Tsung <i>et al.</i> "Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light," <i>J. Virol.</i> 70: 165-171 (1996)		
	FX	Umphress <i>et al.</i> , "Vaccinia virus mediated expression of human APC induces apoptosis in colon cancer cells," <i>Transgenics</i> 4:19-33 (2003)		
	FY	Veijola <i>et al.</i> , "Cloning, Baculovirus Expression, and Characterization of the α Subunit of Prolyl 4-Hydroxylase from the nematode <i>Caenorhabditis elegans</i> ," <i>J. Biol. Chem.</i> 269: 26746-26753 (1994)		
	FZ	Vidal <i>et al.</i> , "Tissue-specific control elements of the Thy-1 gene," <i>EMBO J.</i> 9(3): 833-840 (1990)		
	GA	Watson <i>et al.</i> <i>Molecular Biology of the Gene</i> , 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224		
	GB	Wolffe <i>et al.</i> , "Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination," <i>Journal of Virology</i> 67(8): 4732-4741 (1993) and erratum in <i>Journal of Virology</i> , vol. 67, pp5709-5711 (1993)		
	GC	Wu <i>et al.</i> , "High resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment," <i>PNAS USA</i> 97(15): 8495-8500 (2000)		
	GD	Yang <i>et al.</i> , "Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases," <i>Proc. Natl. Acad. Sci. USA</i> 97(3):1206-1211 (2000)		
	GE	Yang <i>et al.</i> , "Effects of growth medium composition, iron sources and atmospheric oxygen concentrations on production of luciferase-bacterial magnetic particle complex by a recombinant <i>Magnetospirillum magneticum</i> AMB-1," <i>Enzyme Microb. Technol.</i> 29: 13-19 (2001)		
	GF	Yazawa <i>et al.</i> , "Current progress in suicide gene therapy for cancer," <i>World J. Surg</i> 26(7): 783-789 (2002)		
	GG	Yoshida <i>et al.</i> , "Cell growth-inhibitory action of SAGP, an antitumor glycoprotein from <i>Streptococcus pyogenes</i> (Su strain)," <i>Jpn. J. Pharmacol.</i> 45(2): 143-147 (1987)		
	GH	Yoshida <i>et al.</i> , "Characterization of a streptococcal antitumor glycoprotein (SAGP)," <i>Life Sciences</i> 62(12): 1043-1053 (1998)		
	GI	Yoshida <i>et al.</i> , "Growth-inhibitory effect of streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor," <i>Cancer Research</i> 61(16): 6151-6157 (2001)		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002/ 4804B	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Aladar Szalay et al.		
		Filing Date May 19, 2004	Group Art Unit 1632	
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	GJ	Zimmermann <i>et al.</i> , "Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells," <i>Neuron</i> 12: 11-24 (1994)		
	GK	Zolotukhin <i>et al.</i> , "A "Humanized" Green Fluorescent Protein cDNA adapted for high-level expression in mammalian cells," <i>J. Virol.</i> 70:4646-4654 (1996)		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	